Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2022—Memorial Sloan Kettering Cancer Center has awarded GRM Information Management a multiyear contract to store and manage pathology blocks and slides for the hospital’s clinical and research departments.
June 2022—ZeptoMetrix announced the release of its NATtrol SARS-CoV-2 Omicron External Run Control, for research use only, to evaluate the performance of nucleic acid tests for determining the presence of SARS-CoV-2 omicron variant RNA. The control is formulated with purified, intact organisms and is for use with a real-time PCR thermal cycler. The product is available in six 0.5-mL vials and is refrigerator stable at 2° to 8°C.
June 2022—Nova Biomedical launched the CE-marked Nova Max Pro creatinine/eGFR meter system in the EU market. Nova Max Pro is designed to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The meter and creatinine biosensor measure blood creatinine and calculate estimated glomerular filtration rate from a 1.2-μL capillary fingerstick blood sample in 30 seconds. The measuring technology is based on the Nova StatSensor Creatinine technology.
June 2022—Seegene announced that its Allplex RV Master Assay has achieved CE-IVD marking and received approval from Australia’s Therapeutic Goods Administration.
June 2022—PreciseDx announced its AI-enabled digital pathology technology can accurately diagnose Parkinson’s disease in patients prior to severe onset of symptoms.
June 2022—Versant Diagnostics has announced a strategy in which the company will focus on anatomic pathology, precision medicine, and the digital transformation of the industry. The company said it is positioning itself to become the nation’s largest independent physician services company through the acquisition of independent pathology practices, and it will provide capital for practices to convert to digital pathology while maintaining physician leadership.
April 2022—Paragon Genomics announced the release of its Emerging Variant Add-on V2. The panel is designed to be used with existing CleanPlex SARS-CoV-2 products, the company says, to maintain high coverage for variant calling and identification as the virus evolves. It includes added primers for enhanced coverage of critical variants, such as alpha, beta, delta, mu, and omicron, and has been confirmed in silico to cover the defining and characteristic mutations of the omicron sublineages, BA.1, BA.2, and BA.3.
April 2022—Thermo Fisher Scientific has launched two reverse transcription loop-mediated isothermal amplification (RT-LAMP)–based solutions for research use only. The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2, is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal, or nasopharyngeal swab samples. The kit includes two protocols, one for crude sample types with a 30-minute turnaround time and one for increased sensitivity with purified RNA sample types that has a one-hour turnaround time.
April 2022—Alcor Scientific is partnering with Chicago-based health care investor Water Street Healthcare Partners. Water Street will invest in Alcor’s research and development initiatives, product portfolio, and international expansion. Alcor has appointed Jim Post as chief executive officer to lead its next phase of innovation and growth.
April 2022—Verichem Laboratories offers two multilevel, protein-based test kits of clinical reference materials for the calibration or calibration verification of lithium assays. Intended for use with direct and indirect ion-selective electrodes, colorimetric assays, and flame photometers, the Electrolyte Standard Kit and Serum ISE Standard Kit contain NIST-verified gravimetric concentrations for lithium. The liquid-stable, ready-to-use materials can also be used for quality control monitoring, method evaluations, post-maintenance testing, and routine troubleshooting.
